|
Each 1 ml
contains:
Composition:
Etanercept
.......................................................................25
mg
Indications:
For reducing
signs and symptoms and inhibiting the progress of
structural damage in patients with moderately to
severely active rheumatoid arthritis. In combination
with methotrexate in patients who do not respond to
methotrexate alone. To reduce symptoms and signs of
moderately to severely active poly-articular-course
juvenile rheumatoid arthritis (JRA) in patients who have
had an inadequate response to one or more DMARDs.
Description:
Etanercept inhibits TNF activity by competitively
binding to it and preventing interactions with its cell
surface receptors. Elevated levels of TNF have been
found in psoriatic skin lesions, and in synovial
explants and fluid from patients with psoriatic
arthritis.[5-7] Furthermore, TNF levels in
the serum of patients with plaque psoriasis, and in
blister fluids of involved psoriatic skin[9]
have also been shown to be higher than in those of
controls. These values were significantly correlated
with the psoriasis area and severity index (PASI)
scores, and TNF levels were reduced in association with
clinical resolution after effective treatment.
The production of chemokines, and the expression of
adhesion molecules by keratinocytes and vascular
endothelial cells can be stimulated by TNF produced
within psoriatic lesions. These signals then cause
recruitment of additional inflammatory cells into the
plaque. Krueger suggests that TNF may function as part
of a positive feedback loop, which acts to amplify and
sustain the inflammatory process within psoriatic
plaques.[10] Biologic responses that are
induced or regulated by TNF are modulated by etanercept.
It may, therefore, serve to reduce inflammation within
plaques by breaking this cycle.
Dosage:
Adults: 25mg
given twice weekly as a subcutaneous injection 72-96
hours apart. Methotrexate, glucocorticoids, NSAIDs, or
analgesics may be continued during treatment with
etanercept. JRA patients: For paediatric patients (4 to
17 years), dose is 0.4mg/kg (up to a maximum of 25mg per
dose) given twice weekly as a subcutaneous injection
72-96 hours apart. Glucocorticoids, NSAIDs, or
analgesics may be continued during treatment with
etanercept.
Presentations:
Vial 1 ml
MRP Retailer Stockiest
9055.60 7244.00
6519.60 | 
